Genotyping of High Risk Human Papillomavirus (HPV) among cervical precancer and cancer patients

Borna, Nurun Nahar; Tabassum, Shahina; Jahan, Munira; Munshi, Saifullah; Unnesa, Afzal

doi:10.5530/ami.2015.1.5

Cited by 3 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This findings is similar to the present study. 21 In terms of risk factor of hormonal contraception use, a study for International Agency for Research on Cancer, Multicentre Cervical Cancer Study Group by showed that long term use of oral contraceptives could be a cofactor as it increases risk of cervical carcinoma by upto fourfold in women who are positive for HPV DNA. 33 The odds ratio for use of oral contraceptives was 2.82 (95% CI=1.46-5.42) for 5-9 years, and 4.03 (95% CI=2.09-8.02) for use for 10 years or longer.…”

Section: Resultsmentioning

confidence: 99%

“…A study was done at virology department, BSMMU, Dhaka, showed HPV type 16 was detected in 81.82% followed by HPV 18 in 9.09 % and HPV 45 in 6.06% cases of cervical cancer. 21 Conducted a retrospective cross-sectional worldwide study among 38 countries of five continents. 27 Among 46 cases, 42 cases were detected for single infection (91.3%) and only one case was detected for multiple infection (2.2%).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Distribution of Type Specific Human Papilloma Virus DNA Among Women of Cervical Cancer in a Tertiary Level Hospital

Kundu

Khatun

Akter

et al. 2022

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

Background: Infection with high-risk human papilloma virus (HPV) has been recognised as a causal factor for development of cervical pre-cancerous and cancerous lesions. So far more than 150 types of HPV are identified. Their distribution varies from country to country, also from region to region. Background knowledge about the distribution of HPV genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. Objective: The study was aimed to assess the distribution of type specific human papilloma Virus DNA among cervical cancer patients. Methods: The study was a cross sectional, observational and single centred one. It was carried out in the department of gynaecological oncology, of Bangabandhu Sheikh Mujib Medical University (BSMMU). Purposive sampling was done according to the availability of patients. Results: HPV type 16 was detected in 35 cases (76.1%) followed by type 18 in 4 (8.7%) cases of cervical carcinoma. HPV 39, 56 and 68 were also detected, each was in 1 case (2.2 %). It was to be also found that 1 co-infection (2.2%) with HPV 33+35. HPV 16 was detected in 79.4 % of squamous cell carcinoma and in 70.0% of adenocarcinomas. HPV 18 was detected in 5.9 % of squamous cell carcinoma and 20.0% of adenocarcinomas. HPV 39 was detected in one case of small cell carcinoma (100.0%). One case of HPV 68 (2.9%) and one coinfection with HPV 33+35 (2.9 %) were found in squamous cell carcinoma. One case of HPV 56 (10.0%) was detected in adenocarcinoma of cervix. HPV DNA was not found in 3 cases of squamous cell carcinoma of cervix. Conclusion: The distribution of HPV infection among Bangladesh women is similar to other regions of Asia. However, type specific patterns are different. The study findings will guide the formulation of HPV vaccination policies in Bangladesh, impact of vaccination programmes, to predict the efficacy of cost effective prophylactic vaccine, introduction of newer generation vaccine and finally prevention of cervical carcinoma in the country. Bangladesh Med Res Counc Bull 2022; 48(1): 48-55

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Distribution of Type Specific Human Papilloma Virus DNA Among Women of Cervical Cancer in a Tertiary Level Hospital

Kundu

Khatun

Akter

et al. 2022

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

show abstract

“…7 HPV type 16 was detected in 81.82%, type 18 in 9.09% and type 45 in 6.06% cases of cervical carcinoma in Bangladesh. 8 In developed countries, incidence and mortality of cervical cancer has been lowered by effective population-based screening program with Pap smear and or HPV DNA testing. 9 Government of Bangladesh with the support of UNFPA has taken initiative to develop a cervical cancer screening program by visual inspection with acetic acid (VIA), which was considered to be a feasible method for screening cervical cancer in the present socio-economic context.…”

mentioning

confidence: 99%

“…HPV type 16/18 infection was detected in 40.42% of the patients. Borna NN et al8 identify HR HPV genotype among women having CIN and carcinoma. HPV 16 was detected in 81.82%followed by 18 in 9.09%& 45 in 6.06% cases of cervical carcinoma.…”

mentioning

confidence: 99%

Human Papilloma Virus Vaccine for Cervical Cancer Prevention

Sultana

2021

J. Bangladesh Coll. Phys.

View full text Add to dashboard Cite

HPV infection is estimated to be responsible for about 5% of human cancers worldwide. Among all HPV-associated malignancies, cervical cancer is the most important cause of morbidity and mortality worldwide. Cervical cancer is the fourth most common cancer in women worldwide and leading cause of cancer death among females in less developed countries. Persistent HPV infection is a necessary cause of invasive cervical cancer with a prevalence of 99.7% in cervical cancer worldwide.At least 70% of cervical cancers are caused by HPV 16 and HPV 18. HPV vaccination in combination with regular screening offers the most effective way for women to be protected against cervical cancer.The global burden of cervical cancer falls heaviest on the developing countries which haven’t introduced the HPV vaccine as part of their national public health strategy to prevent and control cervical cancer. Different studies showed a drop in the prevalence of HPV associated diseases in vaccinated populations. Sustained efficacy, immunogenicity, and safety of the bHPV vaccine were observed in the final analysis of a follow-up study up to 9.4 years postvaccination. Cervical cancer is a major public health problem in Bangladesh. There has been little success with screening program against cervical cancer in Bangladesh. Therefore, a National HPV Vaccination Program seems to be the window of opportunity to reduce the mortality and morbidity of cervical cancer in Bangladesh. J Bangladesh Coll Phys Surg 2021; 39(2): 123-131

show abstract

Prevalence of Human Papilloma Virus Types 16 and 18 Among Women With Cervical Cancer in Aleppo, Syria

Dandal

Abajy

Alkhalaf

et al. 2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Cervical cancer is the second common type of cancer among women worldwide. Infection by certain types of human papillomavirus infection (HPV) such as HPV 16/18 has been considered as the most significant risk factor for the development of cervical cancer. This study was conducted to determine the prevalence HPV 16/18 in women with and without cervical cancer in Aleppo city, Syria.Methods: Paraffin embedded cervical tissue samples were collected from 113 patients and 40 controls (normal cervix), DNA was extracted and analyzed by PCR for the presence of HPV16/18. Out of 113 cases of cervical carcinoma, 25 cases (22.1%) were carcinoma in situ (CIS), 72 cases (63.7%) were squamous cell carcinomas (SCC) and 16 cases (14.2%) were adenocarcinoma (ADC).Results: HPV 16 and/or 18 DNA was detected in 84 (74.3%) cases out of 113 of cervical cancers, while it was found in only two of the 40 samples in the control group. At the same time, 9 out of 25 (36%) carcinoma in situ, 61 out of 72(84.72%) squamous cell carcinomas, and 14 out of 16 (87.5%) adenocarcinomas, were positive for HPV 16 and/or 18. Conclusion:The frequency of infection with HPV 16 and 18 is high among Syrian women and a vaccine against these two types may be effective in about 74% of cervical cancers in Syria.

show abstract

Genotyping of High Risk Human Papillomavirus (HPV) among cervical precancer and cancer patients

Cited by 3 publications

References 56 publications

Distribution of Type Specific Human Papilloma Virus DNA Among Women of Cervical Cancer in a Tertiary Level Hospital

Distribution of Type Specific Human Papilloma Virus DNA Among Women of Cervical Cancer in a Tertiary Level Hospital

Human Papilloma Virus Vaccine for Cervical Cancer Prevention

Prevalence of Human Papilloma Virus Types 16 and 18 Among Women With Cervical Cancer in Aleppo, Syria

Contact Info

Product

Resources

About